<> "The repository administrator has not yet configured an RDF license."^^ . <> . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake"^^ . "The majority of magnetic resonance contrast agents are restricted to the extracellular domains. For the development of novel, intracellular magnetic resonance contrast agents, we have designed Gd-DOTA derivatives comprising PreS2-TML peptide or ethylguanidinium as carrier moiety. Initial in vitro cell uptake studies with Jurkat cells revealed efficient contrast agent uptake for imaging purposes, in the range of 0.04 fmol/cell (PreS2-TML peptide) to 0.2 fmol/cell (ethylguanidinium) following 2 h incubations at 100 µM."^^ . "2006" . . . . . . . . . . . . . . "Markus"^^ . "Wolf"^^ . "Markus Wolf"^^ . . "Ulrike"^^ . "Bauder-Wüst"^^ . "Ulrike Bauder-Wüst"^^ . . "Rüdiger"^^ . "Pipkorn"^^ . "Rüdiger Pipkorn"^^ . . . . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake (PDF)"^^ . . . "wolf.pdf"^^ . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake (Other)"^^ . . . . . . "indexcodes.txt"^^ . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake (Other)"^^ . . . . . . "lightbox.jpg"^^ . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake (Other)"^^ . . . . . . "preview.jpg"^^ . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake (Other)"^^ . . . . . . "medium.jpg"^^ . . . "PreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake (Other)"^^ . . . . . . "small.jpg"^^ . . "HTML Summary of #6214 \n\nPreS2-TML peptide or guanidinium modified Gd-DOTA exhibits efficient cellular uptake\n\n" . "text/html" . . . "610 Medizin"@de . "610 Medical sciences Medicine"@en . .